Overview
Overview
Gonadorelin dosage supports the restoration of natural LH and FSH release from the pituitary gland, reactivating the hypothalamic‑pituitary‑gonadal (HPG) axis[1]. As a synthetic form of gonadotropin‑releasing hormone (GnRH), gonadorelin stimulates testosterone production in men and promotes ovulation in women when administered in short, pulsatile doses[2][3]. This educational protocol outlines a subcutaneous micro‑dosing approach using a practical dilution for accurate insulin‑syringe measuremen
- Category
- Fertility
- Routes
- subcutaneous
Mechanism
Gonadorelin
Mechanism of action
Mechanism of action
Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin‑releasing hormone (GnRH) secreted by the hypothalamus [1] . When administered in short, pulsatile fashion, it binds to GnRH receptors on pituitary gonadotrophs, triggering the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) [2] [3] . LH stimulates Leydig cells to produce testosterone in men and triggers ovulation in women, while FSH supports spermatogenesis and ovarian follicle development [5] . Unlike continuous GnRH agonist administration, which desensitizes receptors and suppresses gonadotropins, brief periodic dosing preserves the natural pulsatile signaling pattern [4] [6] .
Key research findings
- 01
Synthetic decapeptide identical in sequence to endogenous gonadotropin-releasing hormone (GnRH/LHRH); the molecule and its pituitary GnRH receptor are well characterized (established biochemistry).
- 02
Classic rhesus-monkey work (Belchetz, Plant, Nakai, Keogh, Knobil; Science, 1978) showed intermittent/pulsatile GnRH delivery restores pituitary LH and FSH secretion in hypothalamic-lesioned animals, whereas continuous infusion does not - establishing that the pattern of delivery, not just the amount, governs the gonadotropin response (animal model).
- 03
The same research line showed that continuous GnRH exposure produces receptor desensitization/downregulation and suppresses gonadotropin output - the conceptual basis later used by long-acting GnRH agonists (animal model / mechanistic).
- 04
In human endocrinology, gonadorelin has been used as a research and diagnostic stimulus to probe pituitary gonadotroph responsiveness (the 'GnRH stimulation test') (human study).
- 05
Has a very short circulating half-life (on the order of minutes) due to rapid peptidase cleavage, which is why pulsatile or frequent administration has been studied to mimic physiological signaling (established pharmacology).
Primary source: The research base is mature, built on a deep animal-model foundation (notably Knobil and colleagues' rhesus-monkey studies establishing pulsatile control of the reproductive axis) and extended by human studies using gonadorelin as a stimulus to assess pituitary responsiveness. Mechanistic understanding of pulsatile-versus-continuous signaling is well established; on this platform gonadorelin is handled strictly as a research material.
Pharmacokinetic profile
Single-dose plasma curve over 24h. Shaded band = commonly-cited therapeutic window. Illustrative only.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
Supports endogenous testosterone production by stimulating LH release[1][5].
May help maintain testicular volume and function during exogenous testosterone therapy[7].
Protocol Reference
Protocol reference
Commonly cited research range: 50–200 mcg, daily_for_cycles.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2 (Initiation)
50 mcg
Weeks 3–4 (Titration)
100 mcg
Weeks 5–8 (Maintenance)
100–150 mcg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 (Initiation) | 50 mcg | 5 units (0.05 mL) |
| Weeks 3–4 (Titration) | 100 mcg | 10 units (0.10 mL) |
| Weeks 5–8 (Maintenance) | 100–150 mcg | 10–15 units (0.10–0.15 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 2.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label concentration (1 mg/mL) and date; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Advanced / Post‑Cycle Support Approach
- 06🏷️Route: Subcutaneous injection. Frequency: Daily or every other day for short cycles (limit to ≤14 consecutive days to avoid pituitary desensitization).
- 07❄️WEEK/PHASE DOSE PER INJECTION (MCG) UNITS (ML)
- 08💉Days 1–7 (Burst) 200 mcg 20 units (0.20 mL)
- 09💉Days 8–14 (Taper) 100 mcg 10 units (0.10 mL)
- 10💉Week 3+ (Optional Maintenance) 100 mcg 2–3×/wk 10 units (0.10 mL)
- 11💉Important: Limit consecutive daily dosing to ≤14 days. Extended continuous administration may lead to GnRH receptor desensitization and reduced LH/FSH response[4].
- 12💉Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks and avoid freeze–thaw .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Pulsatile GnRH signaling is well characterized in endocrinology; gonadorelin has been used in clinical research to evaluate and stimulate gonadotropin secretion.
The research base is mature, built on a deep animal-model foundation (notably Knobil and colleagues' rhesus-monkey studies establishing pulsatile control of the reproductive axis) and extended by human studies using gonadorelin as a stimulus to assess pituitary responsiveness. Mechanistic understanding of pulsatile-versus-continuous signaling is well established; on this platform gonadorelin is handled strictly as a research material.
- 01Synthetic decapeptide identical in sequence to endogenous gonadotropin-releasing hormone (GnRH/LHRH); the molecule and its pituitary GnRH receptor are well characterized (established biochemistry).
- 02Classic rhesus-monkey work (Belchetz, Plant, Nakai, Keogh, Knobil; Science, 1978) showed intermittent/pulsatile GnRH delivery restores pituitary LH and FSH secretion in hypothalamic-lesioned animals, whereas continuous infusion does not - establishing that the pattern of delivery, not just the amount, governs the gonadotropin response (animal model).
- 03The same research line showed that continuous GnRH exposure produces receptor desensitization/downregulation and suppresses gonadotropin output - the conceptual basis later used by long-acting GnRH agonists (animal model / mechanistic).
- 04In human endocrinology, gonadorelin has been used as a research and diagnostic stimulus to probe pituitary gonadotroph responsiveness (the 'GnRH stimulation test') (human study).
- 05Has a very short circulating half-life (on the order of minutes) due to rapid peptidase cleavage, which is why pulsatile or frequent administration has been studied to mimic physiological signaling (established pharmacology).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Gonadorelin.
- 01PubMed — GnRH agonists: gonadorelin, leuprolide, and nafarelin – overview of pharmacology and clinical applications View Source
- 02Mayo Clinic — Gonadorelin injection routes and indications for LH/FSH stimulation testing View Source
- 03Wikipedia — Gonadorelin pharmacology, pulsatile dosing, and clinical history View Source
- 04PMC — Gonadotropin‑releasing hormone analogs: pulsatile vs. continuous effects on FSH/LH View Source
- 05PubMed — Gonadotropin treatment for male hypogonadotropic hypogonadism – spermatogenesis and fertility View Source
- 06ScienceDirect — Gonadorelin agonist overview: initial stimulation and subsequent down‑regulation mechanisms View Source
- 07PMC — Preserving fertility in the hypogonadal patient: hCG and GnRH therapy options View Source
- 08PMC — Pulsatile gonadorelin pump induces earlier spermatogenesis in congenital HH men View Source
- 09PubMed — Application of GnRH in hypogonadotropic hypogonadism: diagnostic and therapeutic aspects View Source
- 10Drugs.com — Gonadorelin injectable: uses, side effects, and warnings View Source
- 11PMC — Subcutaneous drug injection review: pharmacologic considerations View Source
- 12CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) View Source
- 13CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source
- 14NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
- 15Pure Lab Peptides — Gonadorelin (2 mg) product page (quality and batch documentation) View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Has been studied in clinical research; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Gonadorelinthis | A synthetic form of gonadotropin-releasing hormone (GnRH) acting on pituitary GnRH receptors to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, supporting the hypothalamic-pituitary-gonadal axis. | subcutaneous | Investigational / RUO |
| HCG | A glycoprotein hormone that binds LH receptors in the gonads, mimicking luteinizing hormone with a substantially longer half-life to stimulate gonadal steroidogenesis. | subcutaneous | Investigational / RUO |
| HMG | A purified gonadotropin preparation providing combined FSH and LH activity, acting on gonadal receptors to support gametogenesis and steroidogenesis. | subcutaneous | Investigational / RUO |
| Oxytocin | A nonapeptide hormone acting on oxytocin receptors; studied for roles in uterine contraction, lactation, and central modulation of social and affiliative behavior. | subcutaneous | Investigational / RUO |
| HGH 191AA | Recombinant human growth hormone (somatropin), a 191-amino-acid protein identical to endogenous GH, acting on GH receptors to drive IGF-1 production and influence growth, metabolism, and tissue repair. | subcutaneous | Investigational / RUO |
| IGF-1 LR3 | A modified analog of insulin-like growth factor-1 with reduced binding to IGF-binding proteins, giving a markedly extended half-life and prolonged activation of IGF-1 receptor anabolic signaling. | subcutaneous | Investigational / RUO |
| Ipamorelin | Binds to ghrelin receptors to stimulate pituitary gland to release growth hormone. Highly selective with minimal side effects. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Identity - it is a synthetic decapeptide with the same amino-acid sequence as naturally occurring gonadotropin-releasing hormone (GnRH, also called LHRH). It is sometimes labeled GnRH or LHRH in the research literature.
Mechanism - it binds GnRH receptors on pituitary gonadotroph cells, prompting release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Research indicates that pulsatile (intermittent) signaling stimulates this output, whereas continuous exposure tends to desensitize the receptors.
Research status - the underlying neuroendocrinology is well established from both animal models (Knobil and colleagues, 1970s-80s) and human studies, and gonadorelin has been used as a research stimulus to evaluate pituitary responsiveness. On this platform it is treated only as a research material, not a therapy.
This platform does not provide human dosing guidance. Research-reported amounts and schedules vary widely by study design; see the protocol/reconstitution reference for this compound for calculation support only. This is not medical advice.
Handling/storage - peptide handling practices vary by supplier and formulation. Lyophilized peptides are generally kept cold and protected from light, with reconstituted material refrigerated and used within a limited window. Follow the supplier's certificate of analysis and product documentation.
Regulatory - Research Use Only. It is not offered for human or veterinary therapeutic use; consult a licensed healthcare professional for any clinical decisions.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.